Encapsulation of vinorelbine into cholesterol-polyethylene glycol coated vesicles: drug loading and pharmacokinetic studies

J Pharm Pharmacol. 2011 Mar;63(3):376-84. doi: 10.1111/j.2042-7158.2010.01227.x. Epub 2011 Feb 8.

Abstract

Objectives: Pegylated liposome formulations of vinorelbine with prolonged circulation half-life (t½) are desirable. However, DSPE-PEG could affect vinorelbine loading into vesicles due to electrostatic interactions. To resolve this problem, chol-PEG was used to prepare pegylated liposomal vinorelbine and the factors affecting drug loading and plasma pharmacokinetics were investigated.

Methods: Vinorelbine was loaded into liposomes using a novel triethylamine 5-sulfosalicylate gradient. The effects of cholesterol and chol-PEG on drug loading were investigated. Pharmacokinetic studies were performed in normal KunMing mice treated with different liposomal vinorelbine formulations. To clarify the effects of chol-PEG on membrane permeability, drug release experiments were performed based on the fluorescence dequenching phenomenon of a fluorescence marker.

Key findings: In contrast to DSPE-PEG, even at high PEG grafting density (∼ 8.3 mol%), chol-PEG had no effect on vinorelbine loading into HSPC/cholesterol (3 : 1, mass ratio) vesicles. However, for the formulations with low cholesterol content (HSPC/cholesterol 4 : 1), loading efficiency decreased with increasing chol-PEG content. In vivo, the vinorelbine t½ of low cholesterol formulations decreased with increasing chol-PEG content, but for high cholesterol liposomes, the maximum vinorelbine t½ was achieved at ∼ 3 mol% chol-PEG grafting density. The resulting vinorelbine circulation t½ was ∼ 9.47 h, which was greater than that of non-pegylated liposomes (∼ 5.55 h). Drug release experiments revealed that chol-PEG might induce membrane defects and concomitant release of entrapped marker, especially at high chol-PEG density.

Conclusions: Through the investigation of the effects of chol-PEG and cholesterol, an optimum pegylated liposomal vinorelbine formulation with prolonged t½ was achieved. In plasma, the membrane defect induced by chol-PEG may counteract the long circulation characteristics that chol-PEG afforded. When these two opposite effects reached equilibrium, the maximum vinorelbine t½ was achieved.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents, Phytogenic / pharmacokinetics*
  • Biological Availability
  • Cholesterol / administration & dosage
  • Cholesterol / analogs & derivatives*
  • Cholesterol / chemistry
  • Chromatography, High Pressure Liquid
  • Coated Vesicles / chemistry*
  • Drug Carriers*
  • Fluorescent Dyes
  • Half-Life
  • Liposomes / administration & dosage
  • Liposomes / chemistry*
  • Mice
  • Polyethylene Glycols / administration & dosage
  • Polyethylene Glycols / chemistry*
  • Spectrometry, Fluorescence
  • Vinblastine / analogs & derivatives*
  • Vinblastine / pharmacokinetics
  • Vinorelbine

Substances

  • Antineoplastic Agents, Phytogenic
  • Drug Carriers
  • Fluorescent Dyes
  • Liposomes
  • polyethylene glycol-cholesterol
  • Polyethylene Glycols
  • Vinblastine
  • Cholesterol
  • Vinorelbine